EPHX2 and Parkinson disease: The sEH inhibitor 1-(1-propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (TPPU) was able to reduce apoptosis in the human PARK2 iPSC-derived neurons, reinforcing the hypothesis that increased sEH expression in the striatum may be implicated in the development of PD.